Understanding What Is Ferritin In Bloodwork And Its Clinical Impact

Published

Table of Contents

Ferritin, a critical protein in human physiology, serves as the primary intracellular iron storage molecule, playing an indispensable role in maintaining iron homeostasis. Beyond its well-documented association with anemia, serum ferritin levels provide clinicians with a window into systemic iron metabolism, inflammation, and metabolic disorders. This biomarker bridges biochemical pathways and clinical diagnostics, offering insights into conditions ranging from iron deficiency to hereditary hemochromatosis and beyond. Its measurement in bloodwork transcends traditional iron studies, serving as a sentinel for both deficiency and overload states, thereby guiding targeted therapeutic interventions.

The evaluation of ferritin extends far beyond simple numerical interpretation, requiring an understanding of its dynamic regulation by hepcidin, transferrin, and cellular iron demand. Pre-analytical variables—such as acute-phase reactants, hemolysis, or recent transfusions—further complicate its diagnostic utility, necessitating a nuanced approach to result interpretation. Clinicians must weigh ferritin’s limitations as a standalone marker against its broader utility in differentiating between iron deficiency anemia, anemia of chronic disease, and iron overload syndromes. This interplay underscores ferritin’s dual role as both a diagnostic tool and a therapeutic monitor, particularly in chronic conditions where iron metabolism is dysregulated.

what is ferritin in bloodwork

Ferritin: Definition and Biological Role

Ferritin is a ubiquitously expressed intracellular protein complex that serves as the primary storage and regulatory form of iron in vertebrates, including humans. Structurally, it consists of 24 subunits arranged in a hollow spherical shell, composed of heavy (H) and light (L) chains in varying ratios depending on tissue type and functional demand. The heavy chain (H) possesses ferroxidase activity, catalyzing the oxidation of ferrous iron (Fe²⁺) to ferric iron (Fe³⁺), which is then deposited as a crystalline mineral core of ferrihydrite (5Fe₂O₃·9H₂O). The light chain (L) facilitates iron nucleation and stabilization within the core. This biochemical architecture enables ferritin to store up to 4,500 iron atoms per molecule, with a dynamic equilibrium between iron uptake, storage, and release, ensuring cellular iron homeostasis.

The primary biological role of ferritin extends beyond passive iron storage; it acts as a redox buffer, preventing iron-mediated oxidative stress by sequestering labile iron and limiting its participation in Fenton chemistry. At the cellular level, ferritin regulates iron availability through coordinated interactions with transferrin (the serum iron transport protein) and hepcidin (the master regulator of systemic iron balance). Iron released from degraded ferritin or intracellular stores is bound by transferrin in the plasma, while hepcidin modulates ferritin synthesis and iron export via ferroportin, thereby integrating systemic and cellular iron demands.

Biochemical Structure and Iron Storage Mechanism

Ferritin’s modular architecture enables its dual function as an iron storage depot and a redox-active protein. The heavy chain (H) contains a ferroxidase center (Fe₂O₂) that oxidizes Fe²⁺ to Fe³⁺, a prerequisite for mineral core formation. The light chain (L) lacks ferroxidase activity but provides binding sites for iron nucleation, stabilizing the ferrihydrite core through electrostatic interactions. The ratio of H:L chains varies by tissue: heart and liver ferritin are enriched in H chains (promoting rapid iron uptake and release), while spleen and muscle ferritin contain higher L chain proportions (favoring long-term storage).

Iron entry into the ferritin shell occurs via channels formed by the H chain’s N-terminal domains, where Fe²⁺ is oxidized and incorporated into the core. Release is mediated by nitric oxide (NO) or hydrogen peroxide (H₂O₂), which disrupt the core’s stability, or by acidification (e.g., in lysosomes during ferritin degradation). The stored iron remains inert under physiological conditions but can be mobilized under conditions of iron demand, such as erythropoiesis or cellular stress.

Iron Storage Capacity:
  • Ferritin: 4,500 Fe atoms/molecule (≈20% of body iron).
  • Hemosiderin: Aggregated ferritin/iron complexes (non-functional storage, insoluble).
  • Transferrin: 2 Fe³⁺ ions/protein (transient transport, not storage).

    • Regulation of Iron Availability: Ferritin, Transferrin, and Hepcidin Interactions

    Ferritin’s role in iron metabolism is tightly coupled to transferrin and hepcidin, forming a triad that governs iron distribution and utilization. Transferrin, a serum glycoprotein, binds Fe³⁺ with high affinity and delivers it to cells via transferrin receptor 1 (TfR1). Upon endocytosis, iron is reduced to Fe²⁺ by steap3 and released into the cytosol, where it can be:
    1. Stored in ferritin (via ferroportin-independent pathways).
    2. Utilized for heme synthesis (e.g., in erythroid precursors).
    3. Exported via ferroportin (regulated by hepcidin).

    Hepcidin, a peptide hormone synthesized in the liver, binds ferroportin, inducing its internalization and degradation. This blocks iron efflux from enterocytes, macrophages, and hepatocytes, thereby reducing plasma iron levels. Conversely, low hepcidin levels (e.g., in iron deficiency or hypoxia) enhance ferroportin activity, increasing iron absorption and release from stores. Ferritin synthesis is iron-responsive: high intracellular iron stabilizes iron regulatory protein 1 (IRP1), which binds to iron-responsive elements (IREs) in ferritin mRNA, preventing translation and limiting iron storage.

    Key Regulatory Pathways:
  • Iron excess → ↑Hepcidin → ↓Ferroportin → ↓Plasma iron → ↑Ferritin synthesis (storage).
  • Iron deficiency → ↓Hepcidin → ↑Ferroportin → ↑Plasma iron → ↓Ferritin (mobilization).

    • Comparison of Iron Storage and Transport Proteins

    The following table contrasts the roles of ferritin, transferrin, and hemosiderin in iron metabolism, highlighting their structural, functional, and physiological distinctions.
    Feature Ferritin Transferrin Hemosiderin
    Primary Role Intracellular iron storage and redox buffering. Serum iron transport to tissues. Insoluble iron storage (degraded/aggregated ferritin).
    Iron Content 4,500 Fe atoms/molecule (≈20% of body iron). 2 Fe³⁺ ions/protein (≈0.1% of body iron). Variable (up to 50% iron by mass, but non-functional).
    Storage Mechanism Ferrihydrite core (Fe³⁺-oxide-hydroxide). Non-covalent binding via bicarbonate bridges. Aggregated ferritin/iron complexes (lysosomal degradation).
    Release Mechanism NO/H₂O₂-mediated core disruption; lysosomal degradation. Endocytosis via TfR1; Fe²⁺ reduction by steap3. Lysosomal breakdown into ferritin monomers.
    Regulation IRP1/IRE-mediated translation; hepcidin-sensitive. Hepcidin-independent; TfR1 expression adjusts demand. Passive accumulation; no active regulation.
    Physiological Impact of Dysregulation
    • ↓Ferritin: Microcytic anemia, mitochondrial iron depletion, impaired immune function.
    • ↑Ferritin: Oxidative stress (via labile iron), organ dysfunction (e.g., liver fibrosis, heart failure).
    • ↓Transferrin saturation: Iron-restricted erythropoiesis (hypochromic anemia).
    • ↑Transferrin saturation: Iron overload (hemochromatosis risk).
    		 Accumulation in macrophages (e.g., secondary hemochromatosis); no direct pathology.

    Systemic Consequences of Ferritin Dysregulation

    Ferritin’s dysfunction extends beyond anemia, influencing mitochondrial function, immune responses, and organ-specific pathology through iron-mediated mechanisms.

    Ferritin Deficiency:

  • Mitochondrial Iron Depletion: Iron is critical for iron-sulfur cluster (ISC) biogenesis in mitochondria, essential for electron transport chain (ETC) complexes I, II, and III. Chronic deficiency impairs ATP production, leading to myopathy, cardiomyopathy, and neurodegeneration (e.g., Friedreich’s ataxia-like symptoms).
  • Immune Dysregulation: Iron is a growth-limiting nutrient for pathogens; low ferritin may paradoxically increase susceptibility to infections (e.g., E. coli, Salmonella) by reducing iron sequestration. Conversely, neutrophil ferritin (H-chain enriched) modulates oxidative burst via iron availability.
  • End

    • what is ferritin in bloodwork - Ilustrasi 2

    Ferritin in Bloodwork: Measurement Methods and Reference Ranges

    Serum ferritin serves as a critical biomarker for assessing iron stores, diagnosing iron-related disorders, and guiding therapeutic interventions. Its quantification relies on highly sensitive immunoassays, which detect circulating ferritin with precision while accounting for pre-analytical variables that may confound results. Understanding these methods, reference ranges, and interfering factors is essential for accurate interpretation in clinical practice.

    The measurement of ferritin in bloodwork primarily employs immunoassay techniques, including enzyme-linked immunosorbent assays (ELISA) and chemiluminescent immunoassays (CLIA). These methods leverage monoclonal or polyclonal antibodies to bind ferritin, enabling quantification through enzymatic or luminescent signals. The analytical sensitivity of these assays typically ranges from 0.5 to 500 ng/mL, with some high-sensitivity variants extending detection limits to <0.1 ng/mL for research or specialized diagnostic applications. The choice of assay influences turnaround time, cost, and suitability for automated laboratory workflows, with CLIA often preferred in high-throughput settings due to its faster results and lower hands-on time.

    Standard Laboratory Techniques for Ferritin Quantification

    Immunoassays form the backbone of ferritin measurement, with ELISA and chemiluminescent methods being the most widely adopted. ELISA utilizes enzyme-substrate reactions to generate colorimetric signals proportional to ferritin concentration, while CLIA employs chemiluminescent substrates for enhanced sensitivity and broader dynamic range. Both methods employ either sandwich or competitive formats, with sandwich assays (e.g., two-site ELISA) offering superior specificity by targeting distinct ferritin epitopes. Automated platforms, such as those from Roche Diagnostics (Elecsys Ferritin) or Abbott Architect, integrate CLIA with liquid-handling systems to reduce variability and improve reproducibility.
    Key Performance Characteristics of Ferritin Assays:
  • Analytical Sensitivity: 0.5–500 ng/mL (varies by assay; high-sensitivity assays may detect <0.1 ng/mL).
  • Precision (CV): <5% for concentrations >10 ng/mL; up to 10% at lower limits.
  • Specificity: Cross-reactivity with other iron-binding proteins (e.g., lactoferrin) is minimal in well-validated assays.
  • Turnaround Time: 1–4 hours for batch processing; <1 hour for automated CLIA systems.
    • Assay standardization remains critical to ensure comparability across laboratories. The International Federation of Clinical Chemistry (IFCC) recommends calibration against certified reference materials (CRMs) to mitigate inter-assay variability. Clinicians should verify assay-specific reference ranges provided by their laboratory, as commercial kits may exhibit batch-to-batch deviations.

    Age-Specific Reference Ranges for Ferritin

    Reference ranges for serum ferritin vary significantly across populations due to physiological differences in iron metabolism, storage, and demand. Below is a structured table summarizing typical ranges for adults, children, and pregnant women, along with clinical implications for interpretation.
    Population Typical Range (ng/mL) Clinical Implications
    Adult Males (18+ years) 30–400 ng/mL
    • <30 ng/mL: Strongly suggestive of iron deficiency, particularly if accompanied by low hemoglobin or MCV <80 fL.
    • 30–100 ng/mL: Borderline; evaluate in conjunction with serum iron, TIBC, and transferrin saturation.
    • >400 ng/mL: Indicates iron overload; consider hereditary hemochromatosis (HH) if transferrin saturation >45% and genetic testing (HFE gene) is positive.
    Adult Females (18–50 years) 10–200 ng/mL
    • <10 ng/mL: Highly specific for iron deficiency, especially in menstruating women or those with heavy menstrual bleeding.
    • 10–30 ng/mL: May reflect early depletion; combine with hepcidin or soluble transferrin receptor (sTfR) for confirmation.
    • >200 ng/mL: Requires exclusion of inflammation, liver disease, or hemochromatosis before diagnosing iron overload.
    Postmenopausal Females (50+ years) 20–300 ng/mL
    • Ranges approach male values due to reduced menstrual iron loss; elevated levels may warrant evaluation for HH or secondary hemochromatosis.
    • Ferritin >300 ng/mL in this group should trigger assessment for hepatic iron index (HII) if hemochromatosis is suspected.
    Children (0–17 years)
    • Infants (0–6 months): 25–200 ng/mL (higher due to maternal iron stores).
    • Toddlers (6–24 months): 7–140 ng/mL (risk of deficiency increases with poor dietary intake).
    • Children (2–17 years): 10–150 ng/mL (lower limits reflect higher iron requirements for growth).
    • <10 ng/mL: Strongly indicative of iron deficiency anemia (IDA), particularly in populations with high prevalence (e.g., low-income settings).
    • >150 ng/mL: May reflect inflammation, lead exposure, or genetic hemochromatosis (rare in pediatrics).
    Pregnant Women
    • First Trimester: 15–150 ng/mL (expanded plasma volume dilutes ferritin).
    • Second/Third Trimester: 10–90 ng/mL (iron demands increase for fetal development).
    • <15 ng/mL: High risk of maternal iron deficiency; supplementation (e.g., ferrous sulfate) and dietary counseling are recommended.
    • >150 ng/mL: May indicate pre-existing iron overload or inflammation; exclude hemochromatosis if clinically indicated.
    Note on Reference Ranges:
  • Values are population-based averages and may not apply to individuals with chronic diseases or genetic disorders.
  • Ethnic variations exist (e.g., lower ferritin thresholds in South Asian populations due to higher prevalence of iron deficiency).
  • Laboratory-specific ranges should be consulted, as assay calibration can shift reference intervals.

    • Pre-Analytical Variables Affecting Ferritin Results

    Several pre-analytical factors can lead to spurious elevation or suppression of serum ferritin, necessitating careful patient preparation and result interpretation. These variables include:
    Common Causes of Ferritin Discrepancies:
  • Inflammation/Infection: Acute-phase reactant behavior elevates ferritin via hepcidin-mediated iron retention; levels may exceed 500 ng/mL in sepsis or rheumatoid arthritis.
  • Hemolysis: Release of intracellular ferritin from lysed erythrocytes can artificially inflate results by up to 20–50%.
  • Recent Blood Transfusion: Exogenous iron increases ferritin within 24–48 hours, peaking at 3–5 days post-transfusion.
  • Liver Disease: Hepatocytes store ~20% of body iron; chronic liver disease (e.g., cirrhosis) elevates ferritin

    Clinical Significance of Elevated Ferritin Levels

    • Elevated serum ferritin levels serve as a critical diagnostic and prognostic marker in clinical medicine, reflecting both pathological iron overload and systemic inflammatory or neoplastic processes. While ferritin is primarily recognized as an acute-phase reactant, its elevation can obscure the distinction between true iron overload (e.g., hereditary hemochromatosis) and secondary hyperferritinemia driven by chronic diseases. Understanding the underlying mechanisms—including inflammatory cytokine-mediated synthesis, metabolic dysregulation, neoplastic proliferation, and iatrogenic factors—is essential for accurate interpretation and targeted therapeutic intervention.

    The clinical significance of elevated ferritin extends beyond iron storage disorders, encompassing a spectrum of conditions where its role as a biomarker intersects with disease pathogenesis. Below, the pathological processes underlying secondary hyperferritinemia are categorized, followed by an analysis of ferritin’s diagnostic limitations and case-based applications in monitoring iron overload disorders.

    Pathological Mechanisms of Secondary Hyperferritinemia

    Elevated ferritin levels in the absence of primary iron overload typically arise from secondary hyperferritinemia, where systemic conditions stimulate hepatic ferritin synthesis independent of iron stores. Key mechanisms include:
  • Cytokine-mediated upregulation: Interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and other pro-inflammatory cytokines enhance ferritin transcription via STAT3 and NF-κB pathways, particularly in chronic inflammation.
  • Hepatocyte stress: Liver diseases (e.g., non-alcoholic steatohepatitis [NASH], alcoholic liver disease) disrupt iron homeostasis by impairing hepcidin regulation, leading to paradoxical iron retention despite elevated ferritin.
  • Neoplastic cell secretion: Malignant cells (e.g., lymphomas, hepatocellular carcinoma) produce ferritin autonomously, contributing to elevated levels even in iron-replete states.
  • Metabolic dysregulation: Insulin resistance and obesity-associated inflammation (e.g., in metabolic syndrome) promote ferritin synthesis through adipokine signaling.

    • These mechanisms often overlap, complicating the differentiation of true iron overload from secondary elevations. Below, a structured categorization of etiologies facilitates clinical assessment.

    Categorization of Elevated Ferritin Causes

    The following flowchart organizes the primary systemic conditions associated with elevated ferritin, grouped by pathophysiological pathways. Each category reflects distinct diagnostic and therapeutic considerations.
    • Inflammatory
      • Chronic inflammatory diseases (rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease)
      • Infections (bacterial endocarditis, HIV, tuberculosis)
      • Acute-phase responses (post-surgery, trauma, burns)
    • Metabolic
      • Non-alcoholic fatty liver disease (NAFLD)/NASH
      • Alcoholic liver disease
      • Metabolic syndrome (obesity, insulin resistance, type 2 diabetes)
      • Hypothyroidism (reduced hepcidin-mediated iron export)
    • Neoplastic
      • Hematologic malignancies (lymphoma, multiple myeloma, leukemia)
      • Solid tumors (hepatocellular carcinoma, colorectal cancer, breast cancer)
      • Paraneoplastic syndromes (e.g., ferritin overproduction by tumor cells)
    • Iatrogenic
      • Iron supplementation or transfusion therapy
      • Glucocorticoid use (induces hepatic ferritin synthesis)
      • Estrogen therapy (enhances iron absorption and ferritin levels)
    Note: Overlap between categories is common (e.g., NASH may coexist with metabolic syndrome and inflammation), necessitating a multimodal diagnostic approach.

    Ferritin as a Biomarker for Systemic Iron Overload

    Ferritin’s primary role as a biomarker for iron overload is well-established, but its utility is limited by functional iron excess—conditions where iron mobilization is impaired despite normal or low total body iron. Key distinctions include:

    - True hemochromatosis: Characterized by primary iron overload (e.g., HFE gene mutations in hereditary hemochromatosis) with elevated ferritin (>300 µg/L in males, >200 µg/L in females) and transferrin saturation (>45%). Treatment with phlebotomy or chelation normalizes ferritin and prevents organ damage.

  • Functional iron excess: Observed in heart failure, chronic kidney disease, and critical illness, where hepcidin-mediated iron retention occurs despite adequate or reduced iron stores. Ferritin may rise secondary to inflammation or hypoxia, leading to misdiagnosis of iron overload.
  • Limitation: Ferritin lacks specificity for iron overload in the presence of acute-phase reactions. Soluble transferrin receptor (sTfR) and sTfR/log ferritin ratio provide complementary data by assessing iron demand independently of inflammation.

    • Key Diagnostic Formula:

    sTfR/log ferritin index = log₁₀(serum ferritin [ng/mL]) / sTfR (mg/L)
    • Index < 1: Likely iron deficiency
    • Index 1–2: Iron-restricted erythropoiesis
    • Index > 2: Iron overload or inflammation
    Monitoring ferritin trends over time is critical for guiding therapy in hereditary hemochromatosis and thalassemia, where treatment goals are individualized based on disease severity and response.

    Case 1: Hereditary Hemochromatosis (HFE C282Y Homozygote)

    Baseline: Ferritin 1,200 µg/L, transferrin saturation 65%, liver fibrosis (F3 on biopsy).
    Intervention: Weekly phlebotomy (500 mL/session) targeting ferritin <50 µg/L.
    Trend:
    • After 12 phlebotomies: Ferritin 80 µg/L, transferrin saturation 30%
    • Plateau at 30 µg/L with maintenance phlebotomy every 3 months
    • Liver biopsy (1 year later): Resolution of fibrosis (F1)
    Interpretation: Ferritin decline correlates with iron depletion and organ improvement, validating therapeutic efficacy.
    Case 2: Thalassemia Major with Secondary Iron Overload
    Baseline: Ferritin 3,500 µg/L, cardiac T2* MRI 10 ms (severe iron overload), Hb 7.5 g/dL.
    Intervention: Deferasirox (30 mg/kg/day) + red blood cell transfusions (every 3 weeks).
    Trend:
    • After 6 months: Ferritin 2,800 µg/L, T2* MRI 15 ms (mild improvement)
    • After 18 months: Ferritin 1,800 µg/L, T2* MRI 25 ms (normalized cardiac iron)
    • Dose adjustment: Deferasirox reduced to 20 mg/kg/day to prevent hepatotoxicity
    Interpretation: Ferritin trends must be interpreted alongside MRI-based iron quantification to avoid overestimation of response, as ferritin may remain elevated due to chronic inflammation from thalassemia.
    Key Insight:
    Ferritin trends in iron overload disorders reflect both iron stores and inflammatory burden. In thalassemia, persistent elevation despite chelation may indicate ineffective erythropoiesis or comorbid liver disease, necessitating alternative imaging (e.g., MRI) or biomarkers (e.g., hepcidin).

    what is ferritin in bloodwork - Ilustrasi 3

    Low Ferritin: Pathophysiology, Diagnostic Evaluation, and Therapeutic Strategies

    Low serum ferritin concentrations reflect depleted iron stores, a critical finding in hematology that necessitates precise diagnostic differentiation and tailored intervention. Ferritin serves as both an iron storage protein and an acute-phase reactant, complicating its interpretation in inflammatory states. While iron deficiency anemia (IDA) remains the most common cause, functional iron deficiency—driven by impaired iron mobilization in chronic diseases—requires distinct diagnostic approaches. Rare genetic disorders, such as atransferrinemia, further broaden the differential, emphasizing the need for a structured workflow to avoid misdiagnosis. Therapeutic decisions hinge on the underlying etiology, with intravenous iron often preferred in populations with malabsorption or inflammation-mediated resistance.

    Differential Diagnosis of Low Serum Ferritin

    The evaluation of low ferritin (<30 µg/L in adults, <15 µg/L in children) prioritizes iron deficiency anemia (IDA), functional iron deficiency (FID), and genetic disorders based on clinical context and laboratory patterns.
    1. Iron Deficiency Anemia (IDA)
      • Primary causes include dietary insufficiency, malabsorption (celiac disease, gastric bypass), or chronic blood loss (menorrhagia, gastrointestinal bleeding).
      • Laboratory confirmation requires:
        • Low hemoglobin (<12 g/dL in women, <13.5 g/dL in men) with microcytic, hypochromic red cells (MCV <80 fL, MCH <27 pg).
        • Low serum iron (<60 µg/dL) and high total iron-binding capacity (TIBC >400 µg/dL), yielding a low transferrin saturation (<16%).
        • Elevated soluble transferrin receptor (sTfR) >8.5 mg/L, indicating increased erythropoietic demand.
      • Key distinction: IDA responds to oral iron (ferrous sulfate 150–200 mg/day) unless absorption is impaired.
    2. Functional Iron Deficiency (FID)
      • Occurs in conditions where iron is sequestered in macrophages or hepatocytes despite adequate stores, such as:
        • Chronic kidney disease (CKD) with erythropoietin-stimulating agent (ESA) therapy.
        • Heart failure (HF) with elevated hepcidin and reduced duodenal iron absorption.
        • Inflammatory bowel disease (IBD) or critical illness with persistent inflammation.
      • Laboratory features:
        • Normal or elevated ferritin (due to acute-phase response) but low transferrin saturation (<20%) and high sTfR/ferritin ratio (>2 mg/g).
        • Elevated hepcidin (>100 ng/mL) in CKD or HF, reflecting impaired iron release from reticuloendothelial cells.
      • Therapeutic implication: Intravenous iron (e.g., ferric carboxymaltose) is preferred due to hepcidin-mediated oral iron resistance.
    3. Rare Genetic Disorders
      • Atransferrinemia (hypotransferrinemia) presents with:
        • Low serum transferrin (<100 mg/dL) and ferritin, despite normal or high iron stores.
        • Neurological symptoms (e.g., dystonia) due to iron accumulation in the brain.
        • Diagnosis confirmed via genetic testing (e.g., Tf gene mutations).
      • Hereditary hemochromatosis (e.g., HFE gene mutations) typically elevates ferritin; low ferritin in these cases suggests coexistent iron loss.

    Diagnostic Algorithm for Low Ferritin

    A systematic approach ensures accurate etiology identification and avoids unnecessary testing. The following steps integrate clinical history, laboratory data, and advanced diagnostics when required.
    1. Initial Assessment
      • Obtain a detailed history of:
        • Symptoms (fatigue, dyspnea, pica, glossitis) and risk factors (dietary habits, menstrual/bleeding history, CKD/HF).
        • Medications (e.g., proton pump inhibitors, ESA therapy).
      • Perform baseline labs:
        • Complete blood count (CBC) with red cell indices (MCV, MCH).
        • Serum iron, TIBC, transferrin saturation, and ferritin.
        • Inflammatory markers (CRP, ESR) to assess acute-phase response.
    2. Differentiating IDA vs. FID
      • If ferritin <30 µg/L with microcytic anemia and low transferrin saturation:
        • Order sTfR to quantify erythropoietic demand. A ratio of sTfR/log ferritin >2 supports IDA.
        • Screen for gastrointestinal blood loss (fecal occult blood test, colonoscopy) or malabsorption (celiac serology, vitamin B12/folate).
      • If ferritin normal/elevated with low transferrin saturation (suggesting FID):
        • Measure hepcidin (if available) to confirm hepcidin-mediated iron trapping.
        • Assess for CKD (eGFR <60 mL/min) or HF (ejection fraction <40%) as primary drivers.
    3. Advanced Diagnostics for Atypical Cases
      • Bone marrow biopsy may be considered if:
        • Diagnosis remains unclear despite initial workup (e.g., suspected sideroblastic anemia or myelodysplastic syndrome).
        • There is discrepancy between ferritin and iron stores (e.g., low ferritin with normal marrow iron).
      • Genetic testing for atransferrinemia or hemochromatosis if clinical suspicion arises.
    4. Therapeutic Decision-Making
      • Oral iron (ferrous sulfate/gluconate) is first-line for IDA unless:
        • Absorption is impaired (e.g., celiac disease, achlorhydria).
        • Patient cannot tolerate gastrointestinal side effects (nausea, constipation).
      • Intravenous iron is indicated for:
        • FID (e.g., CKD on ESA, HF with elevated hepcidin).
        • Malabsorption syndromes or intolerance to oral therapy.
        • Pregnant women with severe anemia (risk of preterm delivery; IV iron reduces adverse outcomes).
      • Monitor response with:
        • Ferritin normalization (target: 50–100 µg/L for IDA, 200–500 µg/L for CKD).
        • Hemoglobin stabilization (goal: >12 g/dL in women, >13.5 g/dL in men).

    Functional Iron Deficiency: Mechanisms and Diagnostic Pitfalls

    Functional iron deficiency arises when iron is biologically unavailable despite adequate or even elevated ferritin stores, primarily due to:
    Hepcidin-mediated iron retention in macrophages and hepatocytes, coupled with increased erythropoietic demand (e.g., ESA therapy in CKD).
    Key Pathophysiological Features:
    1. Hepcidin Overproduction
        <

        Ferritin in bloodwork emerges as a cornerstone of modern hematological and metabolic assessment, its clinical significance extending well beyond its initial characterization as an iron storage protein. From unraveling the complexities of hereditary hemochromatosis to identifying functional iron deficiency in inflammatory states, its measurement offers a multifaceted lens through which to evaluate patient health. The diagnostic workflow surrounding ferritin—spanning from reference range interpretation to advanced biomarker integration—demands a synthesis of biochemical precision and clinical acumen. As research continues to elucidate its role in mitochondrial function, immune modulation, and neoplastic processes, ferritin solidifies its position as a pivotal biomarker in personalized medicine, bridging laboratory data with patient-centered care.

        FAQ

        What does ferritin in bloodwork results mean?

        Ferritin in bloodwork measures the amount of stored iron in your body. It’s the primary test used to diagnose iron deficiency (low ferritin) or iron overload (high ferritin). Normal ranges vary by lab, but typical values are 30–300 ng/mL for men and 10–150 ng/mL for women.

        What is ferritin called on a bloodwork panel?

        Ferritin is typically listed as "ferritin" or "serum ferritin" on blood test results. Some labs may also use the abbreviation "FERR" or "Fe storage" in the report.

        What is high ferritin in bloodwork?

        High ferritin in bloodwork usually indicates excess iron in the body, often due to conditions like hemochromatosis (iron overload), liver disease, or inflammation. It can also result from frequent blood transfusions or certain medications. Untreated high ferritin may damage organs over time.

        What is ferritin in lab work?

        Ferritin in lab work is a protein that stores iron in your body and releases it when needed. Testing ferritin helps doctors assess iron levels, diagnose anemia, or monitor conditions like iron deficiency or iron overload. It’s often ordered alongside other iron tests like TIBC or serum iron.

        What is ferritin in lab results?

        Ferritin in lab results reflects your body’s iron reserves—low levels suggest iron deficiency or anemia, while high levels may indicate iron overload, inflammation, or liver problems. Results are compared to your lab’s reference range for interpretation.

        What is ferritin in lab testing?

        Ferritin in lab testing is a blood test that measures the amount of iron stored in your body’s tissues. It’s used to evaluate iron status, diagnose conditions like anemia or hemochromatosis, and monitor treatment effectiveness. The test is simple, requiring only a blood sample.